Clinical Trials Logo

Clinical Trial Summary

This is a prospective, multicenter, comparative, parallel-group, observational study. There will be 2 cohorts according to pre-transplant dialysis modality (hemodialysis or peritoneal dialysis). In each cohort, subjects will be observed for 12 months. Approximately, 1040 subjects will be enrolled from 8 transplant centers.

Subjects will be enrolled consecutively until the number of subjects in peritoneal dialysis group has been 260. It will take 2 years. In this period, the number of subject in hemodialysis group enrolled in this study will be 780. After finishing the observation of all subjects, to balance clinical and demographic baseline characteristics between the two groups, subjects will be selected in each cohort with 1:1 matched using propensity score method. And then primary and secondary endpoints will be compared between two groups.


Clinical Trial Description

1. STUDY OBJECTIVES AND ENDPOINTS 1.1. Objectives

The primary objective of this study is:

• To compare the incidence of composite outcomes (delayed graft function, functional delayed graft function, primary nonfunction, biopsy-proven acute rejection) of pre-transplant dialysis modality hemodialysis versus peritoneal in recipients of first renal allografts at 1 year posttransplant.

The secondary objectives of this study are:

- To compare the incidence of delayed graft function and functional delayed graft function of pre-transplant dialysis modality hemodialysis versus peritoneal in recipients of first renal allografts at 1 year posttransplant;

- To compare the incidence of composite outcomes biopsy-proven acute rejection of pre-transplant dialysis modality hemodialysis versus peritoneal in recipients of first renal allografts at 1 year posttransplant;

- To compare the incidence of primary nonfunction of pre-transplant dialysis modality hemodialysis versus peritoneal in recipients of first renal allografts at 1 year posttransplant;

- To evaluate the effect of hemodialysis or peritoneal dialysis on graft function in terms of longitudinal change of eGFR calculated with abbreviated MDRD equation at Weeks 8, 16, 24, 32, 40, and 48 after renal transplant;

- To compare the incidence and the duration of hospitalization after kidney transplantation of pre-transplant dialysis modality hemodialysis versus peritoneal in recipients of first renal allografts at 1 year posttransplant;

- To compare the graft loss and subject death rate of pre-transplant dialysis modality hemodialysis versus peritoneal in recipients of first renal allografts at 1 year posttransplant.

1.2. Endpoints

Primary endpoint:

- Composite outcome including;

1. Delayed graft function (defined as the need for dialysis in the first week after transplantation)

2. Functional DGF (defined as the absence of a decrease in serum creatinine level by a minimum of 10% per day during 3 consecutive days in the first postoperative week, not including patients in whom acute rejection, calcineurin inhibitor toxicity, or both, developed within the first week

3. Primary nonfunction (defined as the kidney never achieving function after transplantation)

4. Biopsy proven acute rejection (defined as scute rejection, confirmed by allograft biopsy)

Secondary endpoints:

- eGFR (calculated with abbreviated MDRD equation at Weeks 8, 16, 24, 32, 40 and 48 after renal transplant)

- Hospitalization after kidney transplant (any cause, duration)

- Delayed graft function, functional DGF, Primary nonfunction, biopsy proven acute rejection (definition of each endpoint is described above)

- Graft loss (return to long-term dialysis)

- Subject death (any cause) ;


Study Design


Related Conditions & MeSH terms

  • Acute Rejection of Renal Transplant
  • Delayed Function of Renal Transplant
  • Primary Nonfunction of Renal Transplant

NCT number NCT01513707
Study type Observational
Source Samsung Medical Center
Contact Hayoung Oh
Phone 82-2-3410-3440
Email hayoung.oh@samsung.com
Status Recruiting
Phase N/A
Start date December 22, 2011
Completion date December 2017

See also
  Status Clinical Trial Phase
Withdrawn NCT04665310 - Evaluation of Anti-rejection Drug, Tacrolimus, in African-Americans With Kidney Transplant Phase 4
Recruiting NCT01592253 - Study to Evaluate Safety and Immunologic Biomarker of Rapamune in Patients With Stable Renal Transplant Recipient N/A
Completed NCT01496703 - Reasons for Mycophenolate Mofetil Dose Reduction and Impact on Graft Outcome in Renal Transplant Recipients N/A
Completed NCT00943228 - Intensified Dosing of Cellcept (Mycophenolate Mofetil) in Kidney Transplantation Phase 4
Recruiting NCT05084768 - Dd-cfDNA and Treg in Prediction of Kidney Transplant Acute Rejection
Not yet recruiting NCT02558452 - European Transplant Registry of Senior Renal Transplant Recipients on Advagraf N/A
Not yet recruiting NCT05799716 - Treating Donors With Intravenous Immunoglobulin to Reduce Donor-Derived Infections Phase 4